PharmTech Drug Digest 11.20
News|Articles|February 28, 2017

PharmaCord Launches in Louisville

The new company links and manages aspects of treatment delivery, facilitating access for patients to treatments by serving as a connector between manufacturers, patients, physicians, and payors.

PharmaCord, an independently owned healthcare services company located in Louisville, KY launched on Feb. 26, 2017. PharmaCord provides solutions that link reimbursement services, patient-centric pharmacy, care coordination, clinical services, and patient assistance programs through a technology-based platform. The company links and manages aspects of treatment delivery, facilitating access for patients to treatments by serving as a connector between manufacturers, patients, physicians, and payors.

“As an independently owned, fully funded company, we are developing the technology and tools to provide biopharmaceutical manufacturers with efficient solutions to address the barriers of access for specialty products treating chronic diseases,” said Nitin Sahney, the founder and CEO of PharmaCord, in a statement. “We are investing significantly into the development of our proprietary platform, Intersections. Starting with traditional hub services and consigned pharmacy, we layer on clinical and data analytics to create a powerful tool enabling us to operate efficiently, along with increasing the quality and accessibility of actionable data. Ultimately, branded and customized programs increase conversion to therapy and improve adherence through personalized targeted outreach.”

Source: PharmaCord


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.